The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) ...

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Background: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. Large population-based registries that allow long-term follow-up have been ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...

Cimzia (certolizumab pegol) is a prescription injection that treats Crohn’s disease, arthritis, and other conditions. Learn about side effects, dosage, and more.